Nectar Lifesciences Family Owners Seeks To Sell 44.35% Stake
This article was originally published in PharmAsia News
Executive Summary
The family that is a major stakeholder in Nectar Lifesciences is set to offer to sell its 44.35% share, plus another 11.59% owned by New Silk Route, a global private-equity fund, sources say.